BCR-ABL1 kinase domain mutations: methodology and clinical evaluation

Area of Science:

• Hematology
• Oncology
• Molecular Biology

Background:

• Tyrosine kinase inhibitors (TKIs) have revolutionized chronic myeloid leukemia (CML) treatment.
• A subset of CML patients develop primary or secondary resistance to TKIs.
• BCR-ABL1 kinase domain (KD) mutations are a key mechanism of TKI resistance.

Purpose of the Study:

• To review and compare common laboratory methods for monitoring BCR-ABL1 KD mutations in CML patients.
• To discuss the advantages, disadvantages, and clinical applications of each method for guiding TKI therapy selection.

Main Methods:

• Direct sequencing
• Denaturing High-Performance Liquid Chromatography (D-HPLC)
• Pyrosequencing

Main Results:

• Each method offers different trade-offs in terms of turnaround time, cost, sensitivity, and specificity.
• Accurate quantification of mutant clone size is essential for clinical decision-making.
• Understanding method-specific performance is critical for reliable mutation monitoring.

Conclusions:

• Effective monitoring of BCR-ABL1 KD mutations is vital for optimizing TKI therapy in CML.
• The choice of detection method should be tailored to laboratory capabilities and clinical needs.
• Accurate mutation profiling aids in therapeutic decision-making, particularly for switching TKIs.